Benzinga | Mar 8, 2021 06:10AM EST

HC Wainwright & Co. Upgrades Iovance Biotherapeutics to Buy, Announces $50 Price Target

HC Wainwright & Co. analyst Joseph Pantginis upgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Neutral to Buy and announces $50 price target.